Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | +11.11% | +5.26% | -16.67% |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 2.97M |
---|---|---|---|---|---|
Net income 2023 * | - | Net income 2024 * | - | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.11
x | P/E ratio 2024 * |
-0.12
x | Employees | 18 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.63% |
Latest transcript on Eloxx Pharmaceuticals, Inc.
1 day | +11.11% | ||
1 week | +5.26% | ||
Current month | +16.41% | ||
1 month | +24.98% | ||
3 months | -21.26% | ||
6 months | -78.40% | ||
Current year | -16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Daniel Geffken
DFI | Director of Finance/CFO | 67 | 20-10-31 |
Ali Hariri
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Rubin
BRD | Director/Board Member | 63 | 14-04-30 |
Alan Walts
BRD | Director/Board Member | 64 | 21-03-31 |
Sumit Aggarwal
CEO | Chief Executive Officer | - | 21-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 1 | +11.11% | 6 330 |
24-03-27 | 0.9 | +5.88% | 18,074 |
24-03-26 | 0.85 | -5.56% | 9,183 |
24-03-25 | 0.9 | -1.21% | 1,221 |
24-03-22 | 0.911 | -4.11% | 8,683 |
Delayed Quote OTC Markets, March 28, 2024 at 11:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.67% | 2.97M | |
+3.26% | 108B | |
+10.04% | 104B | |
+6.38% | 23.66B | |
-11.76% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-12.97% | 16.19B | |
+4.53% | 13.72B | |
+34.88% | 12.22B |